NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,406+0.14%BTC$77,436VIX15.44−12.82%live tape · as of 09:00 UTC
The Screen · Technology · Information Technology Services
Accenture
ACN · a US exchange · USD · Market cap $109.6B · 786,000 employees
Accenture plc provides strategy and consulting, industry X, song, and technology and operation services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Screened 2026-09-08 · the tape above runs as of 09:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Accenture holds its Markup at $179.03. Consolidating, no directional conviction, held for 59 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 59 days
Price at the screen
$179.03
Valuation
14.29 trailing · 12.22 forward price to earnings
Values screen
PASS· score 84.3
Beta
1.09
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.51%
Below 33%
Interest-bearing debt is just 12.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.10%
Below 33%
Cash held in interest-bearing accounts and securities is 1.1% of assets, under the one-third limit.
Pass
Receivables
37.53%
Below 49%
Money owed to the company is 37.5% of assets, under the 49% limit.
Pass
Revenue purity
0.48%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 29% discount to our $231.25 fair value, moderate competitive moat, 5.60% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 29.2% margin of safety to the base estimate.
Third-party analyst targets: 25 covering, consensus Buy. The average target sits +3% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The Global IT Expert in an Irish Robe
Imagine a globetrotter, always in the know about the latest tech trends, advising the biggest firms. That's Accenture, an Irish multinational providing a wide array of IT services. Accenture stands out with a forward P/E of 12.4x, which is looking rather frugal for a company that's growing revenue at a steady 6% clip. Its profit margin of 11% and ROE of 24% are indicators of financial health and efficiency.
Despite the market's lukewarm median target of $179, Accenture's current price at $181.35 presents an opportunity, as our fair value sits at $223.75, suggesting a margin of safety of +23%. With a moderate moat and a clean pass on our ethical screen, Accenture appears to be navigating the tech seas with integrity and competence.
Yet, it's not all smooth sailing. The risk here, as with any consultative IT firm, lies in keeping pace with the rapid shifts in technology and maintaining relevance with clients. The market's consensus rating is a buy, but with a modest discrepancy between our valuation and the street's, it's prudent to be mindful of differing perspectives and potential market fluctuations. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ACN trades on a US exchange (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-20Markup · changed$170.73+18.9%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 19.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
2026-07-18Markup$178.25+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
2026-07-16Markup$178.25+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
2026-07-03Markup$178.25+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$178.25Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
